Uncategorized

Novartis Pledges $480M To Expand China Presence, Following Eli Lilly and AstraZeneca

Published

on

Like its pharma peers, Novartis is pouring money into Chinese operations, including expansions and upgrades at an existing manufacturing facility.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version